FranceFrance

French biotech companies suffer from venture capital shortage

29.04.2009

Paris – The French biotechnology industry is facing a major decline in invested venture capital according to an analysis made by France Biotech, the country’s national association of biotech companies.
The latest statistics are sobering. Funding fell by a whopping 79% in 2008 relative to 2007 – a loss of more than EUR500m, down from EUR694m in 2007 to just EUR143m in 12 months. Listed companies took the heaviest hits. In 2008, they collected only EUR12m on the public capital market, a fall of 98%. In comparison, venture capital investments in private companies dropped by “only” 27% to around EUR132m in 2008. The trend for early 2009 appears to show continued degradation, said France Bio­tech.
Philippe Pouletty, the association’s chairman, commented that “in order to underpin the optimism of our entrepreneurs, we must adopt an aggressive stimulus plan for young, innovative companies. Assuming that they can access finance, today’s innovative SMBs will become tomorrow’s multinationals, and thus constitute an essential driver of strong, sustainable economic growth.” France Bio­tech also stated that contrary to claims by French President Nicolas Sarkozy, the French government had actually weakened its support for young, innovative companies in 2009 – pointing to the budget for the OSEO (the French state innovation agency), which was slashed in half, and the reform of a national research tax credit that it says has effectively led to an average annual reduction of 56% for young biotech companies.

FranceFrance

05.01.2012

Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/french-biotech-companies-suffer-from-venture-capital-shortage.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products